SARCOPENIA AND CLINICAL PHENOTYPES IN PSORIATIC ARTHRITIS: CURRENT EVIDENCE AND FUTURE DIRECTIONS

Objectives. To review the evidence on sarcopenia in psoriatic arthritis (PsA) and to examine whether its occurrence differs among the clinical phenotypes of the disease. Methods. Narrative review based on searches of PubMed/MEDLINE, Scopus, Web of Science and Google Scholar up to March 2026, with an updated PubMed search in August 2026. Original studies, systematic reviews, guidelines and consensus documents on muscle mass, muscle strength, physical performance, body composition and sarcopenia in PsA were synthesized qualitatively; mechanistic evidence from other conditions was used only to generate hypotheses. Results. Seven studies reported muscle outcomes in PsA cohorts, one of them combined with axial spondyloarthritis. Sarcopenia frequency ranged from 5.1% to 43.1%, a spread that largely reflects differences in definitions and populations. Compared with controls, patients with PsA had lower muscle mass and higher fat mass, and sarcopenic obesity emerged as a relevant body-composition pattern. No study analyzed sarcopenia by clinical phenotype, and phenotype classification is complicated by overlapping manifestations that may change over time. Systemic inflammation, pain-related disuse, structural damage and obesity provide plausible but untested explanations for possible phenotype-specific differences. Conclusions. Whether sarcopenia differs among PsA phenotypes is unknown. In practice, muscle assessment should be guided by clinical findings rather than by phenotype. Prospective studies using standardized sarcopenia and sarcopenic-obesity criteria, explicit rules for classifying overlapping phenotypes and adjustment for obesity are required before phenotype-oriented screening or rehabilitation can be recommended.

Authors

Institutions

Publication Details

Journal
Arta Medica
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24170169
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

SARCOPENIA AND CLINICAL PHENOTYPES IN PSORIATIC ARTHRITIS: CURRENT EVIDENCE AND FUTURE DIRECTIONS

Liliana Groppa, Eugeniu Russu, Vlada Zanosiev
Arta Medica
Spondyloarthritis Studies and Treatments
article

SARCOPENIA AND CLINICAL PHENOTYPES IN PSORIATIC ARTHRITIS: CURRENT EVIDENCE AND FUTURE DIRECTIONS

Liliana Groppa, Eugeniu Russu, Vlada Zanosiev
article en

Abstract

Objectives. To review the evidence on sarcopenia in psoriatic arthritis (PsA) and to examine whether its occurrence differs among the clinical phenotypes of the disease. Methods. Narrative review based on searches of PubMed/MEDLINE, Scopus, Web of Science and Google Scholar up to March 2026, with an updated PubMed search in August 2026. Original studies, systematic reviews, guidelines and consensus documents on muscle mass, muscle strength, physical performance, body composition and sarcopenia in PsA were synthesized qualitatively; mechanistic evidence from other conditions was used only to generate hypotheses. Results. Seven studies reported muscle outcomes in PsA cohorts, one of them combined with axial spondyloarthritis. Sarcopenia frequency ranged from 5.1% to 43.1%, a spread that largely reflects differences in definitions and populations. Compared with controls, patients with PsA had lower muscle mass and higher fat mass, and sarcopenic obesity emerged as a relevant body-composition pattern. No study analyzed sarcopenia by clinical phenotype, and phenotype classification is complicated by overlapping manifestations that may change over time. Systemic inflammation, pain-related disuse, structural damage and obesity provide plausible but untested explanations for possible phenotype-specific differences. Conclusions. Whether sarcopenia differs among PsA phenotypes is unknown. In practice, muscle assessment should be guided by clinical findings rather than by phenotype. Prospective studies using standardized sarcopenia and sarcopenic-obesity criteria, explicit rules for classifying overlapping phenotypes and adjustment for obesity are required before phenotype-oriented screening or rehabilitation can be recommended.

Arta Medica
Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon